[Partial reimbursement of prescription charges for generic drugs reduces costs for both health insurance and patients].

BACKGROUND: Rising costs of pharmaceuticals are a challenge to the public health care system. In collaboration with a company health insurance with 3143 members we analysed the economic benefit of reduced prescription fees for generic drugs in a 12-month period.
METHODS: Within the observation period 1 euro per prescription of a generic drug was reimbursed to the insurants. On the basis of 5 drug classes the prescribed proportion of generic drugs and the change in prescription pattern was computed. The acceptance of the intervention by the insurants was assessed using anonymous questionnaires.
RESULTS: 42,219 drug prescriptons for insurants of the health insurance company were registered, with an overall cost of euro 843,954.95. In the observation period there was a 45% increase of the proportion of overall costs spent for generic drugs, from euro 78,325.65 to euro 110,419.90, together with a 38% increase of prescriptions of generic drugs. The expenditures for reimbursements of prescription payments amounted to euro 9,984 (euro 1-74 to insurants). In the 5 selected drug classes the proportion of generic drugs increased from 23% before the observation period to 40%, whereby a cost reduction of euro 2.47 per prescription was achieved. Taking into account an overall increase of prescriptions of the selected drugs, a cost reduction from euro 188,811.45 to euro 173,677.15 was accomplished. This intervention was considered useful by 84% of all insurants.
CONCLUSION: Financial incentives for insurants by partial reimbursement of prescription charges are effective for increasing the proportion of generic substitutes and for controlling drug costs.